Decane-1,2-diol is a glycol that is decane bearing two hydroxy substituents located at positions 1 and 2.
产品中实际含有多少
暂无产品标示该成分含量。
含该成分的产品中,10 款将其列在 1% 线之前,25 款列在之后(通常不超过 1%)。
含有此成分的产品
已确认 35 款中的 12 款 · 按含量充足程度排序 · 查看全部 35 款
AriulAriul All Green Feminine Wipes 40 Sheets
NoilyNOILYSKIN YUZU VINEGAR REFRESH SHAMPOO
Rare BeautyRare Beauty Essential Neutrals Eyeshadow Palette
Dr.BangGiWonAll Clear Ampoule
Dr.BangGiWonAll Clear Ampoule Treatment
TOSOWOONGZinc Oxide 10% Cream
YuricaPerfect Cleansing Water Sheet 145g (30 Sheets)
THE SAEMTHE SAEM See & Saw AC Control Deep Cleansing Foam
YBKRelief Hydration Light Foam Cleanser 150ml
DermalogicaDermalogica multivitamin power recovery masque
Biome ActivateHair Repair 9 Advanced Revital Shampoo
DASHUDASHU Classic Style Grooming Tonic Pump 200ml
定义
Decane-1,2-diol is a glycol that is decane bearing two hydroxy substituents located at positions 1 and 2. It has a role as an antioxidant, an anti-inflammatory agent and a human metabolite. It is a volatile organic compound and a glycol. It derives from a hydride of a decane.
来源: PubChem
美国FDA 物质登记 · UNII S57M60MI88 · 登记名称 DECYLENE GLYCOL · 单一化学物质
化妆品中的作用
安全与法规参考
未列入韩国有毒物质 GHS 分类 · 现有化学物质
Reviewed by CIR: Safety Assessment of 1,2-Glycols as Used in Cosmetics
来源: 美国CIR 安全性评估
详细资料——标示名称、识别编号、物性、试验记录、文献
官方标示名称和定义
日本化妆品工业联合会标示名称 デシレングリコール: 本品は、次の化学式で表される二価アルコールである。
来源: 日本化妆品工业联合会标示名称
别名和识别信息
- CAS No.化学物质登记号
- 1119-86-4
- EC No.欧盟化学品目录编号
- 214-288-2
- DTXSID美国EPA化学品编号
- DTXSID601009388
- DTXCID美国EPA化合物编号
- DTXCID50894976
- IUPAC
- Decane-1,2-diol
- 分子式
- C10H22O2
- 分子量
- 174.284 g/mol
实测物性
- 性状
- Hygroscopic solid, [Acros Organics MSDS] · 固体
- 熔点/凝固点
- 44.63 ℃(估算值)
- 分子量
- 174.28
这是对物质本身测得的数值。韩国安全保健公团(KOSHA)的资料仅供编写和审核安全数据表参考,并非原料商品的规格。
来源: PubChem · 韩国安全保健公团 安全数据表
产品实际使用的用途
这是向美国 EPA 申报含该成分的 8 款产品的用途。其中包括化妆品以外的产品,排在前几行的即为该成分的主要用途。
- Softener and conditioner7
- Fragrance1
来源: 美国EPA CompTox
刺激与致敏试验记录
记录有皮肤试验 6 项、眼部试验 1 项。
各项试验结论不一(最多的结论占 20%),因此不能断定该成分有刺激性。 这是对原料本身的试验记录,与成品中所含浓度下的刺激性不同。
查看全部 7 项试验
- SkinIrr2
Skin Irritation · QSAR Predicted - High Frequency of Sensitization
skin sensitisation: in vivo (LLNA) · Screening · equivalent or similar to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) - Moderate or Mild Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to - Low to Moderate Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation) according to EU Method B.6 (Skin Sensitisation) - Not likely to be sensitizing
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) according to EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay) - Ambiguous
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation) according to EU Method B.6 (Skin Sensitisation) - Corrosive or Irritation Persists for > 21 days
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) according to EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to
来源: 美国EPA CompTox
相关文献
- Clustered spiradenomas associated with ALPK1 mutation. · 2026
- Granulomatous cutaneous disease associated with X-linked agammaglobulinaemia: a case report. · 2026
- A case of secondary papuloerythroderma of Ofuji associated with classic Hodgkin lymphoma. · 2026
- Six-month open-label clinical study of a novel topical solution for mild distal lateral subungual onychomycosis. · 2026
- Postoperative pyoderma gangrenosum in a patient with HLA-A26/B51 following hysterectomy and bilateral oophorectomy: a case report. · 2026